| Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ... New England journal of medicine 371 (11), 1005-1015, 2014 | 1559 | 2014 |
| BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, ... Nature 453 (7191), 110-114, 2008 | 1238 | 2008 |
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ... Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013 | 873 | 2013 |
| OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity … DL White, VA Saunders, P Dang, J Engler, ACW Zannettino, ... Blood 108 (2), 697-704, 2006 | 543 | 2006 |
| Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity DL White, VA Saunders, P Dang, J Engler, A Venables, S Zrim, ... Blood, The Journal of the American Society of Hematology 110 (12), 4064-4072, 2007 | 390 | 2007 |
| Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications DK Hiwase, V Saunders, D Hewett, A Frede, S Zrim, P Dang, L Eadie, ... Clinical Cancer Research 14 (12), 3881-3888, 2008 | 233 | 2008 |
| Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib DL White, P Dang, J Engler, A Frede, S Zrim, M Osborn, VA Saunders, ... Journal of clinical oncology 28 (16), 2761-2767, 2010 | 223 | 2010 |
| Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy TP Hughes, S Branford, DL White, J Reynolds, R Koelmeyer, JF Seymour, ... Blood, The Journal of the American Society of Hematology 112 (10), 3965-3973, 2008 | 204 | 2008 |
| CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors A Hughes, J Clarson, C Tang, L Vidovic, DL White, TP Hughes, ... Blood, The Journal of the American Society of Hematology 129 (9), 1166-1176, 2017 | 201 | 2017 |
| Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ... Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018 | 200 | 2018 |
| In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML D White, V Saunders, AB Lyons, S Branford, A Grigg, LB To, T Hughes Blood 106 (7), 2520-2526, 2005 | 199 | 2005 |
| Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy S Angelini, S Soverini, G Ravegnini, M Barnett, E Turrini, M Thornquist, ... haematologica 98 (2), 193, 2013 | 127 | 2013 |
| TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ... Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015 | 116 | 2015 |
| Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells E Nievergall, HS Ramshaw, ASM Yong, M Biondo, SJ Busfield, G Vairo, ... Blood, The Journal of the American Society of Hematology 123 (8), 1218-1228, 2014 | 112 | 2014 |
| Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib LN Eadie, TP Hughes, DL White Clinical Pharmacology & Therapeutics 95 (3), 294-306, 2014 | 110 | 2014 |
| Characterization of leukemias with ETV6-ABL1 fusion M Zaliova, AV Moorman, G Cazzaniga, M Stanulla, RC Harvey, ... Haematologica 101 (9), 1082, 2016 | 91 | 2016 |
| Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells DM Ross, IS Pagani, N Shanmuganathan, CH Kok, JF Seymour, AK Mills, ... Leukemia 32 (12), 2572-2579, 2018 | 82 | 2018 |
| Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia N El Khawanky, A Hughes, W Yu, R Myburgh, T Matschulla, S Taromi, ... Nature communications 12 (1), 6436, 2021 | 79 | 2021 |
| Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity JR Engler, A Frede, VA Saunders, ACW Zannettino, TP Hughes, DL White Leukemia 24 (4), 765-770, 2010 | 79 | 2010 |
| Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those … DL White, J Radich, S Soverini, VA Saunders, AK Frede, P Dang, ... haematologica 97 (6), 907, 2012 | 78 | 2012 |
